First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Post the sale, Patel family has become the single largest promoter shareholder in the company
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The plant, to be built in the Incheon Free Economic Zone in Songdo, Incheon, will be a facility for the manufacture of products such as sterile bags, cell culture media and membrane filters
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
Subscribe To Our Newsletter & Stay Updated
